CoMentis Inc - Company & Market Research Reports

CoMentis specializes in the development of small-molecule drugs to treat neurovascular diseases with a focus on Alzheimer's disease and schizophrenia. They cover the research and development spectrum from initial drug design through manufacturing and clinical trials. The company, with headquarters in South San Francisco, was formed by the merger of Zapaq, Inc. and Athenagen, Inc. in 2006. It is also working on nicotinic acetylcholine receptor modulators for the treatment of cognitive disorders.

From
From
From
Obesity - Pipeline Review, H1 2018 - Product Thumbnail Image

Obesity - Pipeline Review, H1 2018

  • Drug Pipelines
  • 526 Pages
From
Obesity - Pipeline Review, H2 2017 - Product Thumbnail Image

Obesity - Pipeline Review, H2 2017

  • Drug Pipelines
  • 518 Pages
From
Smoking Addiction - Pipeline Review, H2 2017 - Product Thumbnail Image

Smoking Addiction - Pipeline Review, H2 2017

  • Drug Pipelines
  • 89 Pages
From
Smoking Addiction - Pipeline Review, H1 2017 - Product Thumbnail Image

Smoking Addiction - Pipeline Review, H1 2017

  • Drug Pipelines
  • 86 Pages
From
Wet AMD- Pipeline Insight, 2018 - Product Thumbnail Image

Wet AMD- Pipeline Insight, 2018

  • Drug Pipelines
  • 106 Pages
From
Retinal Degeneration - Pipeline Insight, 2018 - Product Thumbnail Image

Retinal Degeneration - Pipeline Insight, 2018

  • Drug Pipelines
  • 217 Pages
From
From
From
From
From
  • 14 Results (Page 1 of 1)
Loading Indicator
adroll